Heron Therapeutics (FRA:AXD2) Tax Provision: €0.0 Mil (TTM As of Mar. 2026)


FRA:AXD2 Heron Therapeutics Inc FRA:AXD2
49 GF Score
Price €0.38
GF Value €1.34
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Heron Therapeutics Tax Provision?

Heron Therapeutics FRA:AXD2 +0.21% 49 Tax Provision is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:AXD2 with a GF Score™ of 49/100 and a GF Value™ of €1.34 (Possible Value Trap). The stock has 4 warning signs investors should review.

Heron Therapeutics's tax provision for the three months ended in Mar. 2026 was €0.0 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Heron Therapeutics Tax Provision Historical Data

* Premium members only.

The historical data trend for Heron Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heron Therapeutics Tax Provision Chart

Heron Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Heron Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:AXD2
49GF Score
Heron Therapeutics Inc FRA:AXD2
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heron Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of €0.0 Mil mean?
Heron Therapeutics (FRA:AXD2) has a Tax Provision of €0.0 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Heron Therapeutics and its competitors.
Is Heron Therapeutics' Tax Provision too high?
Heron Therapeutics' current Tax Provision is €0.0 Mil. Overall, Heron Therapeutics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Heron Therapeutics' Tax Provision compare to ENTX and OKYO?
Heron Therapeutics' Tax Provision of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Heron Therapeutics and its competitors. Heron Therapeutics's current Tax Provision is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heron Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Heron Therapeutics (FRA:AXD2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.34, compared to a current price of €0.38 — trading 71.8% below its estimated fair value. The current Tax Provision is €0.0 Mil. Heron Therapeutics' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Heron Therapeutics (FRA:AXD2), the current Tax Provision is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heron Therapeutics (FRA:AXD2) Overvalued in 2026?

Based on GuruFocus' analysis, Heron Therapeutics stock appears to be undervalued. The current stock price of €0.38 is trading 71.8% below its estimated GF Value™ of €1.34. GuruFocus considers Heron Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:AXD2:

  • Tax Provision: €0.0 Mil
  • GF Value™: €1.34 vs. price of €0.38 (71.8% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the FRA:AXD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heron Therapeutics Business Description

Other Exchanges HRTX:USA0J4V:UKAXD2:Germany
Address 100 Regency Forect Drive, Suite 300, Cary, NC, USA, 27518
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
49GF Score

Get the complete analysis for FRA:AXD2

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.38
Price
€1.34
GF Value